B7.1 expression eliminates tumor resistance to IL-12 gene therapy

Cancer Gene Therapy

Volumn 8, Issue 2, 2001, Pages 118-127

  Heise, Charles P ^a   Shi, Fushun ^a   Albertini, Mark R ^b   Mahvi, David M ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b University of Wisconsin Health   (United States)

Author keywords

B7.1; Gene therapy; Interleukin 12

Indexed keywords

CD28 ANTIGEN; COMPLEMENTARY DNA; INTERLEUKIN 12;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CANCER RESISTANCE; EFFECTOR CELL; FEMALE; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; IMMUNOCOMPETENT CELL; MELANOMA; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR GROWTH; TUMOR REGRESSION;

ANIMALIA; MURINAE;

EID: 0035106024     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700283     Document Type: Article

References (35)

1. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo
2. Molecular cloning of a CD28 cDNA by a high-efficiency COS cell expression system
3. Immune responsiveness to a murine mammary carcinoma modified to express B7-1, interleukin-12, or GM-CSF
4. Antitumor and antimetastatic activity of interleukin-12 against murine tumors
5. A new member of the immunoglobulin superfamily - CTLA-4
6. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity
7. Expression of costimulatory molecules by tumor cells decreases tumorigenicity but may also reduce systemic antitumor immunity
8. B7-1 and interleukin-12 synergistically induce effective antitumor immunity
9. Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumors
10. Interleukin-12-activated natural killer cells recognize B7 costimulatory molecules on tumor cells and autologous dendritic cells
11. Cytotoxic NK1.1 Ag+ alpha beta T cells with intermediate TCR induced in the liver of mice by IL-12
12. Immuno-gene therapy against leukemia: Costimulation of antitumor immunity by the B7.1 molecule
13. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes
14. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation
15. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells
16. Binding of the B-cell activation antigen B7 to CD28 costimulates T-cell proliferation and interleukin-2 mRNA accumulation
17. The role of the CD28 receptor during T-cell responses to antigen
18. The IP-10 chemokine binds to a specific cell surface heparan sulfate site shared with platelet factor 4 and inhibits endothelial cell proliferation
19. Particle-mediated gene transfer of granulocyte-macrophage colony-stimulating factor cDNA to tumor cells: Implications for a clinically relevant tumor vaccine
20. Recombinant IL-12 administration induces tumor regression in association with IFNγ production
21. The CD28 ligand, B7, enhances IL-2 production by providing a costimulatory signal to T cells
22. Interleukin-12 and B7-1 costimulatory molecule expressed by an adenovirus vector act synergistically to facilitate tumor regression
23. Cytokine gene therapy of cancer using gene gun technology: Superior antitumor activity of interleukin-12
24. Gene gun-mediated skin transfection with interleukin-12 gene results in regression of established primary and metastatic murine tumors
25. IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: Enhancement by simultaneous B7-1 expression
26. Cytokine and chemokine expression in tumors of mice receiving systemic therapy with IL-12
27. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4
28. Specificity and longevity of antitumor immune responses induced by B7-transfected tumors
29. CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics
30. Inhibition of angiogenesis in vivo by interleukin-12
31. CTLA-4 ligation blocks CD28-dependent T-cell activation
32. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4
33. Interleukin-12 gene transfer results in CD8-dependent regression of murine CT26 liver tumors
34. Restoration of MHC class I surface expression and endogenous antigen presentation by a molecular chaperone
35. A reassessment of the role of B7-1 expression in tumor rejection